Mesoblast Limited (MESO) News
Filter MESO News Items
MESO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MESO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MESO News From Around the Web
Below are the latest news stories about MESOBLAST LTD that investors may wish to consider to help them evaluate MESO as an investment opportunity.
MESO Stock Surges 80% in a Month After FDA Approval of GVHD DrugMesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older. |
Exploring 3 High Growth Tech Stocks In AustraliaThe Australian market is experiencing a cautious start to the year, with the ASX 200 expected to open slightly lower amid global uncertainties and a weakening Aussie dollar, reflecting broader concerns about economic data and interest rate projections. In this environment, identifying high-growth tech stocks requires careful consideration of factors such as innovative potential and resilience in fluctuating market conditions. |
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. |
Top-Notch Biotech Mesoblast Skyrockets On Immune Condition ApprovalMesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech stock rocketed. |
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host DiseaseThe FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise. |
FDA approves Mesoblast’s Ryoncil for SR-aGvHD treatmentThis is the only MSC therapy approved in the US for any indication. |
Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock SurgesOn Wednesday, the FDA approved Mesoblast Limited’s (NASDAQ:MESO) Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy approved in the U.S. for any indication and the only therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents. Ryoncil contains MSCs, a type of cell that can have various roles in the body and can differentiate into multiple other types of cell |
Mesoblast to be Added to Nasdaq Biotechnology IndexNEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq index. Mesoblast’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024. The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies clas |
DREAM-HF trial sheds positive light on Revascor for ischemic HFGlobalData believes that the study could be of high clinical value to cardiologists. |
3 ASX Growth Companies With Insider Ownership Up To 38%In the last week, the Australian market has been flat, but it has shown impressive growth over the past year with a 16% increase and an annual earnings growth forecast of 13%. In this context, identifying growth companies with significant insider ownership can be particularly appealing as it often indicates confidence from those closest to the business in its future prospects. |